FDA Accepts NDA Resubmission of Diabetes Drug Dapagliflozin FDA Accepts NDA Resubmission of Diabetes Drug Dapagliflozin
Dapagliflozin now looks set to be in a race with empagliflozin to become the second SGLT-2 inhibitor to reach the US market for the treatment of adults with type 2 diabetes. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Forxiga | Health | Jardiance